155 related articles for article (PubMed ID: 37458169)
1. A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region.
So TH; Sharma S; Parij R; Spiteri C; Chawla E; Pandey P; Rajasekaran T
Expert Rev Anticancer Ther; 2023; 23(8):853-863. PubMed ID: 37458169
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
[TBL] [Abstract][Full Text] [Related]
4. Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.
Puente J; García Del Muro X; Pinto Á; Láinez N; Esteban E; Arranz JÁ; Gallardo E; Méndez MJ; Maroto P; Grande E; Suárez C
Target Oncol; 2016 Apr; 11(2):129-41. PubMed ID: 26706236
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
Ding D; Hu H; Shi Y; She L; Yao L; Zhu Y; Zeng S; Shen L; Huang J
Oncologist; 2021 Feb; 26(2):e290-e297. PubMed ID: 32918790
[TBL] [Abstract][Full Text] [Related]
6. A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.
Kanesvaran R; Watt K; Turnbull JD; Armstrong AJ; Wolkowiez MC; George DJ
Clin Genitourin Cancer; 2015 Aug; 13(4):319-327. PubMed ID: 26174223
[TBL] [Abstract][Full Text] [Related]
7. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
8. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.
Edwards SJ; Wakefield V; Cain P; Karner C; Kew K; Bacelar M; Masento N; Salih F
Health Technol Assess; 2018 Jan; 22(6):1-278. PubMed ID: 29393024
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.
Molina AM; Feldman DR; Voss MH; Ginsberg MS; Baum MS; Brocks DR; Fischer PM; Trinos MJ; Patil S; Motzer RJ
Cancer; 2012 Apr; 118(7):1868-76. PubMed ID: 21898375
[TBL] [Abstract][Full Text] [Related]
10. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
[TBL] [Abstract][Full Text] [Related]
11. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.
Cao G; Wu X; Wang Z; Tian X; Zhang C; Wu X; Zhang H; Jing G; Yan T
BMJ Open; 2020 Aug; 10(8):e034626. PubMed ID: 32859659
[TBL] [Abstract][Full Text] [Related]
12. [Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma].
Miller K; Bergmann L; Doehn C; Grünwald V; Gschwend JE; Ivanyi P; Keilholz U; Kuczyk MA
Aktuelle Urol; 2020 Dec; 51(6):572-581. PubMed ID: 33027832
[TBL] [Abstract][Full Text] [Related]
13. [Not Available].
Borchiellini D
Bull Cancer; 2018 Dec; 105 Suppl 3():S242-S254. PubMed ID: 30595153
[TBL] [Abstract][Full Text] [Related]
14. Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA.
Pal SK; Signorovitch JE; Li N; Zichlin ML; Liu Z; Ghate SR; Perez JR; Vogelzang NJ
Int J Urol; 2017 Apr; 24(4):272-278. PubMed ID: 28253548
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R; Alekseev B; Rha SY; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Kopyltsov E; Méndez-Vidal MJ; Kozlov V; Alyasova A; Hong SH; Kapoor A; Alonso Gordoa T; Merchan JR; Winquist E; Maroto P; Goh JC; Kim M; Gurney H; Patel V; Peer A; Procopio G; Takagi T; Melichar B; Rolland F; De Giorgi U; Wong S; Bedke J; Schmidinger M; Dutcus CE; Smith AD; Dutta L; Mody K; Perini RF; Xing D; Choueiri TK;
N Engl J Med; 2021 Apr; 384(14):1289-1300. PubMed ID: 33616314
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
[TBL] [Abstract][Full Text] [Related]
17. Optimal management of metastatic renal cell carcinoma: current status.
Escudier B; Albiges L; Sonpavde G
Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
[TBL] [Abstract][Full Text] [Related]
18. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
Tannir NM; Jonasch E; Albiges L; Altinmakas E; Ng CS; Matin SF; Wang X; Qiao W; Dubauskas Lim Z; Tamboli P; Rao P; Sircar K; Karam JA; McDermott DF; Wood CG; Choueiri TK
Eur Urol; 2016 May; 69(5):866-74. PubMed ID: 26626617
[TBL] [Abstract][Full Text] [Related]
19. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X
J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758
[TBL] [Abstract][Full Text] [Related]
20. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
